Siu Kit Lam
Chief Tech/Sci/R&D Officer at Immunophotonics, Inc.
Siu Kit Lam active positions
| Companies | Position | Start | End |
|---|---|---|---|
Immunophotonics, Inc.
 Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | Chief Tech/Sci/R&D Officer | - | - |
Career history of Siu Kit Lam
Training of Siu Kit Lam
| University of Washington | Doctorate Degree |
| The Johns Hopkins University | Undergraduate Degree |
Statistics
International
| United States | 4 |
Operational
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
| Undergraduate Degree | 1 |
Sectoral
| Consumer Services | 3 |
| Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 1 |
|---|---|
Immunophotonics, Inc.
Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | Health Technology |
- Stock Market
- Insiders
- Siu Kit Lam
- Experience
